Outcomes
Prostate Cancer
ADVERSE EVENTS, DISEASE PROGRESSION, DISEASE, PROSTATE CANCER
The primary clinical endpoint of this study was PSA response rate as outlined by the Prostate Cancer Clinical Trials Working Group 2 (PCWG2).Secondary endpoints included time to disease progression, overall survival (OS), objective disease response by RECIST criteria, and safety. Safety outcomes included frequency and severity of adverse events and serious adverse events.Exploratory endpoints included a correlation of response to satraplatin with changes to a whole blood RNA 6–gene signature score